Vela Technologies (GB:VELA) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Vela Technologies, an early-stage tech investment firm, has announced their stake in Conduit Pharmaceuticals Inc. following Conduit’s entry into an exclusive licensing agreement with AstraZeneca for pioneering treatments. Vela’s investment is currently valued at approximately $170,000, representing 0.46% of Conduit, which plans to initiate Phase II clinical trials for potential first-in-class treatments for autoimmune disorders and idiopathic male infertility.
For further insights into GB:VELA stock, check out TipRanks’ Stock Analysis page.
